Cargando…

Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis

BACKGROUND: Given the increasing use of HER2-targeted antibody–drug conjugates (ADCs) worldwide, the summary of toxicity incidence and profiles of these drugs is crucial to provide reference for clinical application. This meta-analysis aimed to estimate the mean incidences of treatment-related adver...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Zhiwen, Liu, Jinmei, Li, Shijun, Shi, Chen, Zhang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874347/ https://www.ncbi.nlm.nih.gov/pubmed/36712893 http://dx.doi.org/10.1016/j.eclinm.2022.101795

Ejemplares similares

Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials
por: Fu, Zhiwen, et al.
Publicado: (2023)

Antibody drug conjugate: the “biological missile” for targeted cancer therapy
por: Fu, Zhiwen, et al.
Publicado: (2022)

Data reproducibility issues on evidence synthesis of adverse events associated with HER2-targeted antibody–drug conjugates
por: Wu, Dan-Na, et al.
Publicado: (2023)

Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis
por: Zhu, Youwen, et al.
Publicado: (2022)

Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates
por: Fu, Zhiwen, et al.
Publicado: (2023)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Adverse events of antibody–drug conjugates on the ocular surface in cancer therapy
por: Domínguez-Llamas, Sandra, et al.
Publicado: (2023)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022)

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
por: Rainone, Michael, et al.
Publicado: (2023)

Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
por: Albarrán, Víctor, et al.
Publicado: (2022)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
por: Yonesaka, Kimio
Publicado: (2021)

HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia
por: Rainone, Michael, et al.
Publicado: (2023)

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
por: Najjar, Mariana K., et al.
Publicado: (2022)

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2022)

Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
por: Guidi, Lorenzo, et al.
Publicado: (2023)

Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
por: Zhuang, Weiliang, et al.
Publicado: (2023)

Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models
por: Kuo, Wei-Ying, et al.
Publicado: (2018)

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
por: Zhang, Xinling, et al.
Publicado: (2022)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Dendrimer antibody conjugate to target and image HER-2 overexpressing cancer cells
por: Otis, James B., et al.
Publicado: (2016)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells
por: Chiang, Zu-Chian, et al.
Publicado: (2020)

Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody–Drug Conjugates
por: Feuillâtre, Ofelia, et al.
Publicado: (2020)

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
por: Weng, Weining, et al.
Publicado: (2023)

Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events
por: Yu, Yue, et al.
Publicado: (2016)

Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer
por: Yu, Minghui, et al.
Publicado: (2023)

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
por: Ding, Haozhong, et al.
Publicado: (2021)

Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
por: Kim, Hyun Jung, et al.
Publicado: (2020)

Natural Product Alantolactone Targeting AKR1C1 Suppresses Cell Proliferation and Metastasis in Non-Small-Cell Lung Cancer
por: Fu, Zhiwen, et al.
Publicado: (2022)

Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
por: Maneiro, María, et al.
Publicado: (2020)

Quantum Dots: Synthesis, Antibody Conjugation, and HER2-Receptor Targeting for Breast Cancer Therapy
por: Fatima, Iqra, et al.
Publicado: (2021)

Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Lin, Yuxi, et al.
Publicado: (2023)

Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis
por: Chacón, Matías Rodrigo, et al.
Publicado: (2018)

Long-term efficacy and adverse effects of cannabidiol in adjuvant treatment of drug-resistant epilepsy: a systematic review and meta-analysis
por: Liu, Shengyi, et al.
Publicado: (2023)

EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors
por: Capone, Emily, et al.
Publicado: (2021)

Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy
por: Kang, Jeffrey C., et al.
Publicado: (2019)

Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells
por: Liang, Keying, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vg2lqjdujae122n0l194nf01r0